Case report: Long-term efficacy and safety of semaglutide in the treatment of syndromic obesity in Prader Willi syndrome - case series and literature review
IntroductionPrader-Willi syndrome (PWS) is the most prevalent cause of syndromic obesity. Obesity development in PWS is driven by dysfunction in neural pathways involved in satiety and reward, dysregulation in hormones regulating satiety and food intake, altered body composition and reduced energy e...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-01-01
|
| Series: | Frontiers in Endocrinology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fendo.2024.1528457/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832592678806618112 |
|---|---|
| author | Andrijana Koceva Andrijana Koceva Katarina Mlekuš Kozamernik Katarina Mlekuš Kozamernik Andrej Janež Andrej Janež Rok Herman Rok Herman Simona Ferjan Simona Ferjan Mojca Jensterle Mojca Jensterle |
| author_facet | Andrijana Koceva Andrijana Koceva Katarina Mlekuš Kozamernik Katarina Mlekuš Kozamernik Andrej Janež Andrej Janež Rok Herman Rok Herman Simona Ferjan Simona Ferjan Mojca Jensterle Mojca Jensterle |
| author_sort | Andrijana Koceva |
| collection | DOAJ |
| description | IntroductionPrader-Willi syndrome (PWS) is the most prevalent cause of syndromic obesity. Obesity development in PWS is driven by dysfunction in neural pathways involved in satiety and reward, dysregulation in hormones regulating satiety and food intake, altered body composition and reduced energy expenditure, as well as the presence of various hormone deficiencies. As hyperphagia, satiety dysfunction and consequent food-seeking behaviors are intrinsic to PWS, obesity management can be challenging.Case seriesWe present a long-term follow-up of treatment with GLP-1 receptor agonist (GLP-1 RA) semaglutide in three patients with PWS without diabetes, one of whom had previously undergone metabolic surgery. Semaglutide treatment at dosages from 0.5 mg to 2 mg weekly demonstrated variable efficacy, from preventing further weight gain in patient 1, to achieving weight loss of up to 14.4% and 11% relative to baseline, in Patient 2 and Patient 3. It was well tolerated, even after metabolic surgery.ConclusionLong-term randomized placebo-controlled trials with larger sample sizes are needed to provide stronger evidence on the long-term efficacy and safety of semaglutide for obesity treatment in PWS as well as explore the potential synergistic effects of GLP-1 RA treatment combined with other therapeutic interventions. |
| format | Article |
| id | doaj-art-e1338b458ac64e6b877a58b5ca4acc90 |
| institution | Kabale University |
| issn | 1664-2392 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Endocrinology |
| spelling | doaj-art-e1338b458ac64e6b877a58b5ca4acc902025-01-21T05:43:34ZengFrontiers Media S.A.Frontiers in Endocrinology1664-23922025-01-011510.3389/fendo.2024.15284571528457Case report: Long-term efficacy and safety of semaglutide in the treatment of syndromic obesity in Prader Willi syndrome - case series and literature reviewAndrijana Koceva0Andrijana Koceva1Katarina Mlekuš Kozamernik2Katarina Mlekuš Kozamernik3Andrej Janež4Andrej Janež5Rok Herman6Rok Herman7Simona Ferjan8Simona Ferjan9Mojca Jensterle10Mojca Jensterle11Department of Endocrinology and Diabetology, University Medical Center Maribor, Maribor, SloveniaFaculty of Medicine, University of Maribor, Maribor, SloveniaDepartment of Endocrinology, Diabetes and Metabolic Diseases, University Medical Center Ljubljana, Ljubljana, SloveniaFaculty of Medicine, University of Ljubljana, Ljubljana, SloveniaDepartment of Endocrinology, Diabetes and Metabolic Diseases, University Medical Center Ljubljana, Ljubljana, SloveniaFaculty of Medicine, University of Ljubljana, Ljubljana, SloveniaDepartment of Endocrinology, Diabetes and Metabolic Diseases, University Medical Center Ljubljana, Ljubljana, SloveniaFaculty of Medicine, University of Ljubljana, Ljubljana, SloveniaDepartment of Endocrinology, Diabetes and Metabolic Diseases, University Medical Center Ljubljana, Ljubljana, SloveniaFaculty of Medicine, University of Ljubljana, Ljubljana, SloveniaDepartment of Endocrinology, Diabetes and Metabolic Diseases, University Medical Center Ljubljana, Ljubljana, SloveniaFaculty of Medicine, University of Ljubljana, Ljubljana, SloveniaIntroductionPrader-Willi syndrome (PWS) is the most prevalent cause of syndromic obesity. Obesity development in PWS is driven by dysfunction in neural pathways involved in satiety and reward, dysregulation in hormones regulating satiety and food intake, altered body composition and reduced energy expenditure, as well as the presence of various hormone deficiencies. As hyperphagia, satiety dysfunction and consequent food-seeking behaviors are intrinsic to PWS, obesity management can be challenging.Case seriesWe present a long-term follow-up of treatment with GLP-1 receptor agonist (GLP-1 RA) semaglutide in three patients with PWS without diabetes, one of whom had previously undergone metabolic surgery. Semaglutide treatment at dosages from 0.5 mg to 2 mg weekly demonstrated variable efficacy, from preventing further weight gain in patient 1, to achieving weight loss of up to 14.4% and 11% relative to baseline, in Patient 2 and Patient 3. It was well tolerated, even after metabolic surgery.ConclusionLong-term randomized placebo-controlled trials with larger sample sizes are needed to provide stronger evidence on the long-term efficacy and safety of semaglutide for obesity treatment in PWS as well as explore the potential synergistic effects of GLP-1 RA treatment combined with other therapeutic interventions.https://www.frontiersin.org/articles/10.3389/fendo.2024.1528457/fullPrader-Willi syndromeobesityGLP-1 receptor agonistsemaglutidemetabolic surgery |
| spellingShingle | Andrijana Koceva Andrijana Koceva Katarina Mlekuš Kozamernik Katarina Mlekuš Kozamernik Andrej Janež Andrej Janež Rok Herman Rok Herman Simona Ferjan Simona Ferjan Mojca Jensterle Mojca Jensterle Case report: Long-term efficacy and safety of semaglutide in the treatment of syndromic obesity in Prader Willi syndrome - case series and literature review Frontiers in Endocrinology Prader-Willi syndrome obesity GLP-1 receptor agonist semaglutide metabolic surgery |
| title | Case report: Long-term efficacy and safety of semaglutide in the treatment of syndromic obesity in Prader Willi syndrome - case series and literature review |
| title_full | Case report: Long-term efficacy and safety of semaglutide in the treatment of syndromic obesity in Prader Willi syndrome - case series and literature review |
| title_fullStr | Case report: Long-term efficacy and safety of semaglutide in the treatment of syndromic obesity in Prader Willi syndrome - case series and literature review |
| title_full_unstemmed | Case report: Long-term efficacy and safety of semaglutide in the treatment of syndromic obesity in Prader Willi syndrome - case series and literature review |
| title_short | Case report: Long-term efficacy and safety of semaglutide in the treatment of syndromic obesity in Prader Willi syndrome - case series and literature review |
| title_sort | case report long term efficacy and safety of semaglutide in the treatment of syndromic obesity in prader willi syndrome case series and literature review |
| topic | Prader-Willi syndrome obesity GLP-1 receptor agonist semaglutide metabolic surgery |
| url | https://www.frontiersin.org/articles/10.3389/fendo.2024.1528457/full |
| work_keys_str_mv | AT andrijanakoceva casereportlongtermefficacyandsafetyofsemaglutideinthetreatmentofsyndromicobesityinpraderwillisyndromecaseseriesandliteraturereview AT andrijanakoceva casereportlongtermefficacyandsafetyofsemaglutideinthetreatmentofsyndromicobesityinpraderwillisyndromecaseseriesandliteraturereview AT katarinamlekuskozamernik casereportlongtermefficacyandsafetyofsemaglutideinthetreatmentofsyndromicobesityinpraderwillisyndromecaseseriesandliteraturereview AT katarinamlekuskozamernik casereportlongtermefficacyandsafetyofsemaglutideinthetreatmentofsyndromicobesityinpraderwillisyndromecaseseriesandliteraturereview AT andrejjanez casereportlongtermefficacyandsafetyofsemaglutideinthetreatmentofsyndromicobesityinpraderwillisyndromecaseseriesandliteraturereview AT andrejjanez casereportlongtermefficacyandsafetyofsemaglutideinthetreatmentofsyndromicobesityinpraderwillisyndromecaseseriesandliteraturereview AT rokherman casereportlongtermefficacyandsafetyofsemaglutideinthetreatmentofsyndromicobesityinpraderwillisyndromecaseseriesandliteraturereview AT rokherman casereportlongtermefficacyandsafetyofsemaglutideinthetreatmentofsyndromicobesityinpraderwillisyndromecaseseriesandliteraturereview AT simonaferjan casereportlongtermefficacyandsafetyofsemaglutideinthetreatmentofsyndromicobesityinpraderwillisyndromecaseseriesandliteraturereview AT simonaferjan casereportlongtermefficacyandsafetyofsemaglutideinthetreatmentofsyndromicobesityinpraderwillisyndromecaseseriesandliteraturereview AT mojcajensterle casereportlongtermefficacyandsafetyofsemaglutideinthetreatmentofsyndromicobesityinpraderwillisyndromecaseseriesandliteraturereview AT mojcajensterle casereportlongtermefficacyandsafetyofsemaglutideinthetreatmentofsyndromicobesityinpraderwillisyndromecaseseriesandliteraturereview |